about
The Impact of the Newly Licensed Dengue Vaccine in Endemic CountriesThree Decades of Dengue Surveillance in Five Highly Endemic South East Asian Countries.The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison StudyThe Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.An economic evaluation of vector control in the age of a dengue vaccinePlant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity.Ancient oncogenesis, infection and human evolution.Development of Antibody Therapeutics against Flaviviruses.Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case studyAntiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)
P2860
Q28354105-B9EA1ECA-A38C-472E-9B85-55BE9ABC777BQ30235948-5F9B94B1-CBB2-4B70-BB3C-47E9A9511E92Q36206692-7466F466-204D-4492-BF35-1A81D09A6626Q36206719-06AED924-8A89-48F0-ADF7-9B29711F2D74Q38156746-C07BE515-5AC4-43C1-8AB3-F05750AC7872Q40078229-1D9CB7FD-E055-4D4E-B309-8851D2BAC374Q45844303-1A40E75E-8A6F-4708-9342-571A0458444DQ47558158-B6CBC702-7EAF-4F09-9F1D-B3F012A73E24Q56475810-49D9B378-436F-48DF-AAEE-E920F9943228Q56479686-E350911C-21E4-4F2A-BA45-53C55959A61F
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
SAGE committee advice on dengue vaccine.
@en
type
label
SAGE committee advice on dengue vaccine.
@en
prefLabel
SAGE committee advice on dengue vaccine.
@en
P1476
SAGE committee advice on dengue vaccine.
@en
P2093
Tikki Pang
P304
P356
10.1016/S1473-3099(16)30167-0
P577
2016-08-01T00:00:00Z